Cost Plus Drugs began selling TheracosBio’s Brenzavvy (bexagliflozin), an FDA-approved Type 2 diabetes medication, on July 13, according to a news release. Its other branded drugs are IBSA Pharma’s Tirosint; Johnson & Johnson’s Invokana, Invokamet and Invokamet extended-release; and Pfizer’s Duavee, Estring, Premarin, Premphase and Prempro.
Mark Cuban Cost Plus Drugs adds 10th brand-name drug
Mark Cuban Cost Plus Drug Co. added its 10th brand-name drug to its portfolio that includes about 1,000 generics.
From prescription to therapy: How Mount Sinai and U of Miami Health speed patient access
Presenters: Sherif ElMasry, ForusGary I. Kleiner, M.D., Ph.D., University of Miami Health SystemAngela J Lamb, M.D., Mount Sinai
Comments are closed.